Autolus Therapeutics plc (AUTL): who owns it and who trades it
As of Nov 16, 2026, AUTL insiders reported 1 open-market sale worth $15.7K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Cintia Piccina (U.S. CCO & Country Gen M), with $15.7K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Autolus Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns AUTL
84 funds and institutions reported AUTL shares worth $212M at the end of Q2 2026, about 50% of the company. The largest holder is Mak Capital One LLC with 12.6%.
Funds and institutions (13F) 50%Everyone else 50%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Mak Capital One LLC | 33.62M | 12.63% | $53.8M | No change |
| Blackstone Inc. | 20.49M | 7.70% | $32.8M | No change |
| Syncona Portfolio Ltd | 16.64M | 6.25% | $26.6M | No change |
| Armistice Capital, LLC | 15.00M | 5.64% | $24M | -5% |
| Tetragon Partners GP Ltd | 9.50M | 3.57% | $15.2M | No change |
| Schroder Investment Management Group | 7.83M | 2.94% | $12.9M | -17% |
| Frazier Life Sciences Management, L.P. | 4.45M | 1.67% | $7.1M | No change |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 3.36M | 1.26% | $5.4M | No change |
| Laurion Capital Management LP | 3.32M | 1.25% | $5.3M | No change |
| Renaissance Technologies LLC | 1.98M | 0.75% | $3.2M | -14% |
| Bank of America Corp | 1.61M | 0.60% | $2.6M | -13% |
| BlackRock, Inc. | 1.60M | 0.60% | $2.6M | +8% |
| UBS Group AG | 1.52M | 0.57% | $2.4M | +16% |
| Morgan Stanley | 1.26M | 0.47% | $2M | +34% |
| Millennium Management LLC | 1.22M | 0.46% | $2M | +498% |
| Cetera Investment Advisers | 1.16M | 0.43% | $1.9M | +3% |
| Balyasny Asset Management L.P. | 972,748 | 0.37% | $1.6M | +0% |
| JPMorgan Chase & Co | 913,239 | 0.34% | $1.5M | New |
| Alphabet Inc. | 698,262 | 0.26% | $1.1M | No change |
| Citadel Advisors LLC | 695,890 | 0.26% | $1.1M | +51% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, AUTL insiders reported $0 of open-market purchases and $15.7K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Cintia Piccina | U.S. CCO & Country Gen M | Sale | 6,713 | $2.34 | $15.7K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Cintia Piccina | U.S. CCO & Country Gen Manager | – | $15.7K | Sep 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AUTL short interest
Low short interest. 3.2% of AUTL shares are sold short: about 1 share in 31. Over the last 12 reports the number of shares short went down 38%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 8.63M AUTL shares were sold short, 3.2% of the shares outstanding, down 4.8% from the report before. At the average daily volume of 1.83M shares, buying them all back would take about 4.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 8.63M | 3.24% | -5% | 1.83M | 4.7 |
| Oct 15, 2026 | 9.07M | 3.41% | +8% | 1.77M | 5.1 |
| Sep 30, 2026 | 8.40M | 3.16% | +1% | 1.48M | 5.7 |
| Sep 15, 2026 | 8.33M | 3.13% | -8% | 1.72M | 4.8 |
| Aug 31, 2026 | 9.08M | 3.41% | -13% | 2.52M | 3.6 |
| Aug 14, 2026 | 10.48M | 3.94% | -24% | 4.39M | 2.4 |
| Jul 31, 2026 | 13.79M | 5.18% | -9% | 828,901 | 16.6 |
| Jul 15, 2026 | 15.14M | 5.69% | +21% | 1.44M | 10.5 |
| Jun 30, 2026 | 12.49M | 4.69% | -7% | 942,339 | 13.3 |
| Jun 15, 2026 | 13.48M | 5.06% | +5% | 1.32M | 10.2 |
| May 29, 2026 | 12.79M | 4.80% | -9% | 1.85M | 6.9 |
| May 15, 2026 | 14.02M | 5.27% | +7% | 1.63M | 8.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Autolus Therapeutics company events
Autolus Therapeutics filed 14 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, auditor, job cuts). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Aug 3, 2026AnnouncementThe Company announced an increase in full year 2026 guidance for AUCATZYL® net product revenue to $140 million to $150 million, from between $120 million to $135 million. Filing
- Aug 3, 2026AgreementAutolus Therapeutics plc entered into a Note Purchase Agreement and Guaranty with certain subsidiaries of the Company, as guarantors, the noteholders party thereto and Perceptive Credit Holdings V, LP, as administrative agent for the noteholders (in such capacity, together with permitted successors… Filing
- Jun 29, 2026VoteReported shareholder vote results. Filing
- Jun 9, 2026AnnouncementAutolus Therapeutics plc published its UK Annual Report and Accounts for the year ended December 31, 2025 and distributed a notice of its annual general meeting to be held on June 29, 2026, a form of proxy and its UK Annual Report to its ordinary shareholders. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Apr 29, 2026Job cutsAnnounced job cuts or other exit costs. Filing
- Apr 16, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
- Apr 8, 2026AnnouncementShared information with investors. Filing
- Mar 27, 2026ResultsReleased financial results. Filing
- Jan 26, 2026AgreementAutolus Limited, a wholly owned subsidiary of Autolus Therapeutics plc (the “ registrant ”, and together with Autolus Limited, the “ Company ”), entered into a Master Service Agreement with AGC Biologics S.p.A for the manufacture and supply of lentiviral vector, a raw material which is critical for… Filing
- Jan 12, 2026AnnouncementThe Company announced preliminary unaudited AUCATZYL net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025. Filing
- Dec 2, 2025LeadershipAutolus Therapeutics plc announced that its board of directors, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Ryan Richardson to serve as a Class I director of the Company, effective December 1, 2025 and continuing until the Company’s 2028… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Autolus Therapeutics financials
Famous investors that hold AUTL
4 of the 50 well-known investors we track reported holding AUTL in their latest 13F filing. The largest position is Jim Simons's, worth $4.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.49M | $4.8M | 0.0% | +26% |
| Israel Englander · Millennium Management | Q3 2026 | 2.16M | $4.2M | 0.0% | +77% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.63M | $3.2M | 0.0% | +134% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 134,420 | $261K | 0.0% | +89% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named AUTL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 5.2% |
| Nov 16, 2026 | MAK Capital Fund LP | 13G/A | 11.5% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 5.2% |
| Nov 16, 2026 | MAK Capital Fund LP | 13G/A | 11.5% |
| Nov 12, 2026 | Qatar Investment Authority | 13G/A | 3.5% |
| Nov 12, 2026 | Qatar Investment Authority | 13G/A | 3.5% |
| Nov 10, 2026 | BXLS V - Autobahn L.P. | 13D/A | 7.6% |
| Nov 10, 2026 | BXLS V - Autobahn L.P. | 13D/A | 7.6% |
Questions about Autolus Therapeutics plc (AUTL) stock
Who owns the most AUTL stock?
The largest reported owner of Autolus Therapeutics plc (AUTL) is Mak Capital One LLC, with 12.6% of the company. In total, 84 funds and institutions reported holding AUTL at the end of Q2 2026, together about 50% of the shares. See the largest owners.
Are AUTL insiders buying or selling?
In the last 12 months, AUTL insiders reported no open-market purchases and 1 sale worth $15.7K. The latest trade was on Sep 2, 2026. See every trade.
What is the short interest in AUTL?
As of Oct 30, 2026, 8.63M AUTL shares were sold short, 3.2% of the shares outstanding, down 4.8% from the report before. At the average daily volume of 1.83M shares, buying them all back would take about 4.7 trading days (days to cover). See the history.
Which famous investors hold AUTL?
4 of the 50 well-known investors we track reported AUTL in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $4.8M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.